Usana Health Sciences INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NYSE
Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have reported a beneficial ownership of 5.19% in USANA Health Sciences Inc., holding 958,520 shares.
NYSE
The Vanguard Group has reported a complete divestment of its beneficial ownership in USANA Health Sciences Inc. following an internal corporate realignment.
NYSE
SCHEDULE 13G/A: Dimensional Fund Advisors Reports 4.6% Stake in USANA
Dimensional Fund Advisors LP has filed an amended Schedule 13G, disclosing a 4.6% beneficial ownership stake in USANA Health Sciences Inc. as of December 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Reports 4.4% Stake in USANA Health Sciences
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 4.4% beneficial ownership stake in USANA Health Sciences Inc. common stock as of December 31, 2025.
NYSE
Pzena Investment Management, LLC has reported a 6.6% beneficial ownership stake in USANA Health Sciences Inc. common stock.
NYSE
Dimensional Fund Advisors LP has reported a passive 5.0% beneficial ownership stake in USANA Health Sciences Inc. common stock.
NYSE
The Vanguard Group has filed an amendment to its Schedule 13G, reporting a beneficial ownership of 5.43% in USANA Health Sciences Inc.'s common stock.
NYSE
The Vanguard Group has filed an updated Schedule 13G, reporting a 7.26% beneficial ownership stake in USANA Health Sciences Inc. as of March 31, 2025.